

Special Issue

Molecular Imaging in Neurology and Oncology: Radiopharmaceuticals for PET and SPECT

Message from the Guest Editor

Molecular imaging methods that use radionuclide-labelled compounds to assess in vivo biological functions are constantly evolving thanks to innovations in related sciences such as chemistry and radiochemistry, biochemistry, and bioengineering. Therefore, non-invasive nuclear medicine techniques, namely, positron emission tomography (PET) and single-photon emission computed tomography (SPECT), can image a broad spectrum of pathophysiological processes by means of the large diversity of available radiotracers ranging from radionuclide ions to small inorganic and organic molecules, and further to biomolecules and particles. The journal *Pharmaceuticals* invites both reviews and original articles shedding light upon the latest developments in radiopharmaceutical sciences applied to neurology and oncology, two medical specialties that are particularly benefiting from nuclear medicine technologies.

Guest Editor

Dr. Guillaume Becker

1 CarMeN Laboratory, INSERM, INRA, INSA Lyon, University Claude Bernard Lyon 1, Lyon, France

2 GIGA-Cyclotron Research Center-in vivo imaging, University of Liège, Allée du 6 Août, B30, 4000 Liege, Belgium

Deadline for manuscript submissions

closed (30 November 2021)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/73585

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)